Retinal vein occlusion leads to increased expression of VEGF in the ocular milieu which is responsible for retinal neovascularisation and increase in retinal vascular permeability. This results in breakdown of the blood-retinal-barrier and subsequent development of macular edema. All three currently available anti-VEGF agents (ranibizumab, bevacizumab and aflibercept) have been successfully used in management of macular edema secondary to retinal vein occlusions. The CRUISE and BRVO studies compared two different doses of ranibizumab (0.3mg versus 0.5mg) to sham injections in patients with macular edema secondary to retinal vein occlusions and showed significant improvement in visual acuity in treated group versus the control group [2, 3] . This led to the US Food and Drug Administration (US-FDA) approval of ranibizumab (0.3mg) for the treatment of macular edema secondary to retinal vein occlusions in 2010. In the VIBRANT trial, monthly intravitreal aflibercept injections provided significantly greater visual benefit compared with macular grid laser in eyes with macular edema secondary to BRVO [4] . Aflibercept was approved for the management of macular edema following CRVO in September 2012. Thus, introduction of anti-VEGF agents has been considered as the beginning of a new era in the treatment of macular edema secondary to retinal vein occlusions as these agents target the disease at the molecular level.
Corticosteroids: Current role
Corticosteroids have a role in the treatment of macular edema secondary to retinal vein occlusions because of their anti-inflammatory and anti-angiogenic properties. There has been an interest in the use of local corticosteroid therapy in the management of both BRVO and CRVO. The SCORE study compared two different doses of intravitreal triamcinolone (1mg and 4mg) to the standard of scare which is observation in CRVO and macular laser treatment in BRVO. SCORE-CRVO study concluded that patients in corticosteroid group are five times more likely to have substantial visual gain in visual acuity as compared to observation group. The SCORE-BRVO study concluded that corticosteroid and macular laser treatment has similar impact on vision [5, 6] . The GENEVA study evaluated the use of sustainedrelease dexamethasone implant in the management of macular edema due to retinal vein occlusions [7] . Based on the results of the GENEVA trial, intravitreal dexamethasone implant (OZURDEX®) received FDA approval for the treatment of macular edema secondary to retinal vein occlusions in 2009.
Future Directions
Recently, a number of trials have been initiated with an attempt to reduce the treatment burden by employing a combination of the available therapies. In the recently published WAVE trial, ultra-wide field fluorescein angiography was performed among patients with retinal vein occlusions. The study evaluated the use of wide field image-guided peripheral retinal photocoagulation (of the targeted non-perfused retina) combined with ranibizumab. However, the results of the study did not show any significant reduction in the total number of intravitreal injections required over a period of 12 months [8] . Similarly, the RELATE trial evaluated higher dose of ranibizumab (2.0mg) and laser therapy in the management of macular edema in retinal vein occlusions. The results showed that higher dose of ranibizumab and laser therapy offered no additional benefits in eyes with retinal vein occlusions [9] . A number of newer agents are being studied for the management of retinal vein occlusions. triamcinolone. It is being evaluated for its role in patients with chronic cystoid edema due to retinal vein occlusions [10] . As there is progressive visual impairment due to degeneration of photoreceptors in eyes with retinal vein occlusions, stem cell therapy is currently being investigated for the treatment of macular edema in BRVO and CRVO [11] .
